JB
FLXN

Julian Baker’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Julian Baker’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-146,642
Closed -$2.83M – 138
2015
Q4 		$2.83M Buy
+146,642
New +$2.55M 0.02% 96

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Julian Baker's FLXN Position: Q1 2016 in Review

Julian Baker sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2016, closing a stake of 146,642 shares — an estimated $2.83M sold.

Julian Baker first reported a position in FLXN in Q4 2015 and held it in 1 quarter. The position peaked at $2.83M in Q4 2015. 65 funds tracked by Wall St. Rank hold FLXN as of Q1 2016.

  • Julian Baker reported no remaining Flexion Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Julian Baker sold 146,642 Flexion Therapeutics, Inc. shares in Q1 2016, an estimated $2.83M.
  • Julian Baker first reported a position in Flexion Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Julian Baker's Flexion Therapeutics, Inc. position peaked at $2.83M in Q4 2015.
  • 65 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2016.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.